- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04536883
MICRA - Pilot Study (MICRA)
Contribution of Confocal Microscopy in the Diagnosis of Acute Cell Rejection ACR in Lung Transplantation: Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
During the patient's usual follow-up, if an ACR is suspected and it is decided to perform an endoscopy with transbronchial biopsies, the protocol is presented to the patient by the doctor in charge. If the patient agrees to participate in the study, consent is obtained. Collection on arrival of the patient's sex, age, weight, height, respiratory background leading to the patient's lung transplant.
According to the department's protocol: carrying out functional respiratory tests, a biological assessment (CBC, hemostasis and CRP) and a chest x-ray prior to the procedure except if there is another chest imaging dating less than 24 hours testifying to the absence of pneumothorax. Premedication with hydroxyzine, insertion of a peripheral venous route, verification of the patient's identity, anticoagulant or anti-aggregating treatment and potential allergy.
The fibroscopy is carried out according to the usual procedure of the service, namely: realization of 1 to 2 mg of hypnovel intravenously depending on the patient's tolerance, introduction of the fiberscope preferably via the nasal route, if impossible or contraindicated, the oral route is possible with the use of a bite block to protect the fiberscope. Visualization of the mobility of the vocal cords, trachea, carina and right and left bronchial tree up to the segmental level. Identification of the quality of the sutures and the possible presence of bronchial stenosis. Realization of a bronchial trap with bacteriological and mycological analysis. Performing a bronchoalveolar lavage (90cc of physiological serum, preferably in the middle lobe) with anatomopathological, virological, bacteriological, mycological and mycobacteriological analysis.
At this stage, the confocal microscopy procedure begins:
Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.
Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.
The fibroscopy procedure is then resumed as usual in the department, namely:
Performing 5 to 6 transbronchial biopsies. The number of biopsies depends on the patient's tolerance and the occurrence of complications such as hemorrhage or pneumothorax. Checking at the end of the procedure for the absence of active intra-bronchial bleeding, followed by a frontal chest X-ray to check for the absence of pneumothorax (examination carried out routinely even in the event of bronchial endoscopy with simple BTB). If there are no complications and if the pathological analysis of the lung biopsies does not conclude that there is an acute cellular rejection, the patient can return home at the end of the day. If the pathologist concludes that there is a rejection or that there is a complication, the patient remains hospitalized for the time necessary for medical treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nantes, France
- CHU Nantes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Follow-up by the Nantes University Hospital team for a lung transplant
- Having given their consent
- Clinical suspicion of acute cellular rejection OR systematic fibroscopy post transplantation to screen for acute asymptomatic rejection
Exclusion Criteria:
- Minor or adult patient under guardianship and protected person
- FEV1 <40% of theoretical at the time of inclusion
- Bleeding disorder
- Pneumothorax existing before the performance of the fibroscopy
- Active smoking less than 1 year old
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Microscopy confocal
The fibroscopy is carried out according to the usual procedure of the service. During the fibroscopy, for all patient, the confocal microscopy procedure begins. After the end of confocal procedure, 5 to 6 transbronchial biopsies are performing |
At this stage, the confocal microscopy procedure begins: Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus. Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF. The fibroscopy procedure is then resumed as usual in the department, namely: |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine ability of the operator
Time Frame: 1 day
|
The main objective of this study is to determine the ability of the operator to obtain and interpret confocal microscopy images per procedure. analyzes in real time the images provided by the confocal microscopy probe. the operator determines the presence of intra-alveolar inflammatory cells and evaluates the vessel wall. On the basis of this per-procedure analysis, if the operator considers the interpretation possible, he declares whether he concludes that the presence of pulmonary inflammation is consistent with the diagnosis of rejection. |
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse effects
Time Frame: 1 day
|
assess the adverse effects: patient comfort, procedure time and complications (hemoptysis, pneumothorax
|
1 day
|
ability of confocal microscopy to eliminate acute cellular rejection
Time Frame: 1 day
|
assess the ability of confocal microscopy to eliminate acute cellular rejection
|
1 day
|
Correlation confocal microscopy and proven infection
Time Frame: 1 day
|
to assess the correlation of the parameters observed in confocal microscopy associated with a proven infection (main differential diagnosis of acute cell rejection)
|
1 day
|
Correlation inter operator
Time Frame: 1 day
|
The correlation between the analysis per procedure by the operator and the analysis of the images by the second a posteriori expert
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Adrien TISSOT, MD, CHU Nantes
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RC20_0201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rejection Lung Transplant
-
Stanford UniversityKaiser Foundation Research InstituteCompletedLung Transplant Rejection | Cardiac Transplant RejectionUnited States
-
Hopital FochRecruitingLung Transplant Rejection | Lung Transplant Failure | Lung Transplant; Complications | Lung Transplant Failure and RejectionFrance
-
University of ZurichRecruitingLung Transplant Rejection | Lung Transplant Failure and RejectionSwitzerland
-
Medical University of ViennaRecruitingLung Transplant Rejection | Antibody-mediated RejectionAustria
-
Duke UniversityBristol-Myers SquibbWithdrawnLung Transplant Rejection | Antibody-mediated Rejection
-
Washington University School of MedicineBristol-Myers Squibb; National Heart, Lung, and Blood Institute (NHLBI)CompletedLung Transplant Rejection | Antibody-mediated RejectionUnited States
-
Xemed LLCChildren's Hospital of Philadelphia; University of PennsylvaniaRecruiting
-
University of AlbertaRecruitingLung Transplant RejectionCanada, United States, Australia, Austria, Czechia, Poland
-
Paris Translational Research Center for Organ TransplantationHopital FochCompleted
-
John F. McDyer, MDCompletedLung Transplant RejectionUnited States
Clinical Trials on microscopy confocal
-
Johns Hopkins UniversityAmerican Society for Gastrointestinal Endoscopy; Pentax Medical CorporationCompletedBarrett's Esophagus, Esophageal Intraepithelial NeoplasiaUnited States, Germany
-
Singapore General HospitalCompletedDiffuse Parenchymal Lung DiseasesSingapore
-
Centre Hospitalier Universitaire de Saint EtienneCompletedMicrocirculation | Blood CirculationFrance
-
Memorial Sloan Kettering Cancer CenterRecruitingHead and Neck Cancer | Squamous Cell Carcinoma (SCC) of the Oral CavityUnited States
-
Julie DawsonCompletedBasal Cell CarcinomaUnited Kingdom
-
Technical University of MunichCharite University, Berlin, Germany; Technische Universität DresdenCompleted
-
Massachusetts General HospitalNational Institutes of Health (NIH); Infectious Diseases Institute, UgandaCompleted
-
Lucid, Inc.Memorial Sloan Kettering Cancer Center; University of Rochester; Loma Linda University and other collaboratorsCompletedMelanoma | Skin Cancer | Lentigo MalignaUnited States
-
Institut de Cancérologie de LorraineRecruitingSquamous Cell Carcinoma of Head and Neck | Basal Cell Carcinoma of SkinFrance